Navigation Links
ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data,Presented at International Myeloma Workshop
Post Your Comments:
(Date:5/15/2008)...monstrated in Blacks, Hispanics/Latinos, People ..., PARSIPPANY, N.J., May 15 /- Daiich...d at the American Society of,Hypertension,s Twenty...w,Orleans demonstrated that the powerful combinati...mil) safely and effectively helped,patients across...
(Date:5/15/2008)...d with a newly cleared device to identify the, li... are associated with complicatio...5 /- InfraReDx, Inc. today,announced ... Mich., have,successfully used its LipiScan(TM) Co...rdiac catheterization. This is the first patient i...
(Date:5/15/2008)...May 15 /- Ergonex Pharma today,announ...ation (FDA) has,granted orphan drug designation to... hypertension (PAH). Terguride is currently being ...urope., "The FDA,s grant of orphan drug designati... our development program by offering regulatory,c...
(Date:5/15/2008)...y 15 /- Tigris Pharmaceuticals,Inc. ...earch and,Development Agreement (CRADA) with the N...linical and preclinical development of AFP-464, an...P-464 is converted to,metabolites which bind coval...tosis., This is part of a four-year CRADA encompa...
Breaking Medicine Technology:Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 2Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 4Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 5Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 6Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 7First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 2First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 3First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 4Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension 2Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute 2Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute 3The Quigley Corporation Reports First Quarter 2008 Results Increases Investment in Pharmaceutical R 26D Future 17613 1The Quigley Corporation Reports First Quarter 2008 Results Increases Investment in Pharmaceutical R 26D Future 17613 2The Quigley Corporation Reports First Quarter 2008 Results Increases Investment in Pharmaceutical R 26D Future 17613 3The Quigley Corporation Reports First Quarter 2008 Results Increases Investment in Pharmaceutical R 26D Future 17613 4The Quigley Corporation Reports First Quarter 2008 Results Increases Investment in Pharmaceutical R 26D Future 17613 5Pharmacyclics Reports Third Quarter 2008 Financial Results 17611 1Pharmacyclics Reports Third Quarter 2008 Financial Results 17611 2Pharmacyclics Reports Third Quarter 2008 Financial Results 17611 3Pharmacyclics Reports Third Quarter 2008 Financial Results 17611 4Pharmacyclics Reports Third Quarter 2008 Financial Results 17611 5Pharmacyclics Reports Third Quarter 2008 Financial Results 17611 6Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and Operating Performance 4831 1Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and Operating Performance 4831 2Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and Operating Performance 4831 3Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and Operating Performance 4831 4Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and Operating Performance 4831 5Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and Operating Performance 4831 6Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and Operating Performance 4831 7Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and Operating Performance 4831 8Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and Operating Performance 4831 9Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and Operating Performance 4831 10Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and Operating Performance 4831 11Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and Operating Performance 4831 12Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and Operating Performance 4831 13Strong Double Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol Myers Squibb Company 4829 1Strong Double Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol Myers Squibb Company 4829 2Strong Double Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol Myers Squibb Company 4829 3Strong Double Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol Myers Squibb Company 4829 4Strong Double Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol Myers Squibb Company 4829 5Strong Double Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol Myers Squibb Company 4829 6Strong Double Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol Myers Squibb Company 4829 7Strong Double Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol Myers Squibb Company 4829 8Strong Double Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol Myers Squibb Company 4829 9Strong Double Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol Myers Squibb Company 4829 10Strong Double Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol Myers Squibb Company 4829 11Strong Double Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol Myers Squibb Company 4829 12Strong Double Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol Myers Squibb Company 4829 13Strong Double Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol Myers Squibb Company 4829 14Strong Double Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol Myers Squibb Company 4829 15Strong Double Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol Myers Squibb Company 4829 16Strong Double Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol Myers Squibb Company 4829 17Strong Double Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol Myers Squibb Company 4829 18Strong Double Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol Myers Squibb Company 4829 19
...-- Berlex, Inc., a U.S.,affiliate of Bayer Scherin...of a retrospective study demonstrating that the pr...develop in response to,Betaseron(R) (interferon be...n patients with multiple sclerosis (MS).(1) The st... three continents. It,is the largest dataset ever ...
... 3, 2007 - Repros,Therapeutics Inc. (NasdaqGM:RPRX...of Proellex(TM), an oral drug being developed to,r...ggests that,treatment with Proellex results in a s...ptoms associated with uterine,fibroids and is gene... This 12 week, double-blind study compared two dos...
Other Medicine Technology:Large Study Shows that Presence of Neutralizing Antibodies Did Not,Predict Clinical Response to Betaseron Treatment 2Large Study Shows that Presence of Neutralizing Antibodies Did Not,Predict Clinical Response to Betaseron Treatment 3Large Study Shows that Presence of Neutralizing Antibodies Did Not,Predict Clinical Response to Betaseron Treatment 4Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 2Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 3Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 4Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 5
(Date:5/16/2008)...Frail Seniors and People With,Disabilities, OAKLA...sands of,homecare workers across the state are out...s to hours of service, wages and benefits,which w...rkers and the,people they serve deeper into povert...eniors and people with disabilities from Schwarzen...
(Date:5/16/2008)...ational HIV Vaccine Awareness Day, May,18, WASHIN... years into the,AIDS epidemic, someone is newly in...nday, May 18, HIV Vaccine Awareness Day, AIDS Acti...Institute of Allergy and Infectious,Disease (NIAID... everyone,to help end the AIDS epidemic by partici...
(Date:5/16/2008)...ntsworth plc (LSE: HNT), "the Group",a leading in...ications,group headquartered in London, released i...roup,s performance in the first quarter 2008 (the ...ollows below., 15 May 2008, ...rim Management Statement, Record net n...
(Date:5/16/2008)...More in 2007, WASHINGTON, May 16 /PRNewswire-USNe...ancer deaths, the National Cancer Institute (NCI) ...n lung cancer research in 2007,according to updat... today., The two other federal agencies with sign...sease Control and Prevention (CDC) and the,Departm...
Breaking Medicine News(10 mins):Health News:Homecare Workers Outraged by Proposed Cuts, Wage Reductions 2Health News:AIDS Action Urges Everyone to Help End the AIDS Epidemic by Being Part of the Search for an HIV Vaccine 2Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 2Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 3Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 4Health News:Lung Cancer Still Lowest in Federal Funding 2
...al new cancer treatment might cause a cancer revol...eatment targets tumors with radioactive microspher...therapy is most often used for bowel cancer patien... but is expected to be extended to other cancers. ...
...ho are bogged down with fertility problems can now...n conscientiously engaged in the study of a protei...e fertilized egg in the uterus. The team studied ...e menstrual cycles of 12 women with previous histo...
...ng to the recent research conducted by Dr. Michael...that death rates due to lung cancer among non smok...ver smoked had higher lung cancer death rates than... Americans. Lung cancer is by far the biggest canc...
...a's Health and Human Services Minister, Lara Giddi...cedures in the department. // This was part of a n...ceston this morning to 200 of the health departmen...ers. The main aim is to reduce the number of appr...
Other Medicine News:Health News:A Revolutionary New Treatment For Cancer Available In Australia 2
...d human blood cells provides a simple, cost effect...ation of urine prior to microscopic analysis in co...tion of urine sediment is a moderately complex tes...and quantitative values are provided for standardi...
...enience for urinalysis quality control one bottle...product for dipstick, hCG, and microscopics qualit...nine and microalbumin. Values are provided for mic... qualitative results for hCG are also included. Di...
... is ideal for most life science applications, espe...tented* PathCheck sensor technology senses the dep...alizes the absorbance value to a 1-cm pathlength. ... obtained in a conventional spectrophotometer. ,...
The Clearblue Easy Ovulation Test detects the surge of "luteinizing hormone in your urine, which usually happens 24 to 36 hours before you ovulate (release an egg). That means youll know the 2 best
Medicine Products: